CD30 Expression Associated With Diffuse Large B-Cell Lymphoma Prognosis

In a study published in the Journal of Oral Pathology & Medicine, researchers examined the prognostic value of varying CD30 expressions in patients with diffuse large B-cell lymphoma (DLBCL). The team, directed by Carla Isabelly Rodrigues-Fernandes, MSc, found that CD30 positivity appeared to be a functional predictor for a higher survival rate and more favorable prognosis in patients.

The quantitative meta-analysis used cut-off values of >0% and >20% to assess the frequency of CD30 expression in pooled data from studies on patients with DLBCL. The investigators aimed to uncover potential associations between expression of CD30, pathological features, and overall survival.

Patients with a >0% cut-off value were considered to be positive for CD30 expression. The team observed significant associations between the protein expression and: a lower number of extra-nodal sites affected by the malignancy; an Ann Arbor advanced stage categorization; a lack of MYC and BCL2 translocations; and a lower Easter Cooperative Oncology Group (ECOG) performance. Using the >20% cut-off value, the range of patients who were considered positive for CD30 narrowed to 2.5–36.7. This stratification showed significant associations with: a lower number of affected extra-nodal sites; an Ann Arbor stages III/IV classifications; non-GCB tumors; a lack of MYC and BCL2 translocations, and a lower ECOG score.

Within the context of either cut-off value, the study’s authors concluded that “CD30 expression was significantly associated with a better survival rate,” and suggested that expression of the protein may be a valuable biomarker for the prognosis of patients with DLBCL.